Mikio Ohtsuka

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Pathogenic Link Between Hydroa Vacciniforme and Epstein-Barr Virus–Associated Hematologic Disorders

Keiji Iwatsuki, Masataka Satoh, Takenobu Yamamoto et al. · Archives of Dermatology · 2006 · 190 citations

Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma

Natsuko Matsumura, Mikio Ohtsuka, Nobuyuki Kikuchi et al. · Acta Dermato Venereologica · 2015 · 100 citations · Full text

Immune Regulation, Immunology, Immunotherapeutics +16

Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma

Mikio Ohtsuka, Takako Miura, Tatsuhiko Mori et al. · JAMA Dermatology · 2015 · 93 citations

Nivolumab Therapy, Melanoma, Pathology +5

A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid

Masayuki Amagai, Shigaku Ikeda, Takashi Hashimoto et al. · Journal of Dermatological Science · 2016 · 93 citations

Vaccination, Veterinary Vaccine, Autoimmune Disease +6